Tonix Pharmaceuticals to Participate in Two Investor Conferences in March

Rhea-AI Summary

Tonix Pharmaceuticals (Nasdaq: TNXP) said management will participate in two investor conferences in March 2026: a company presentation at TD Cowen on March 4, 2026 and 1x1 meetings at Barclays from March 10–12, 2026.

A live webcast of the March 4 presentation will be available on the company's Investor Events page, with a replay accessible for 90 days. The company highlighted its recently approved flagship product TONMYA and a CNS and immunology pipeline including TNX-2900, TNX-4800, and TNX-1500.

Key Figures

TONMYA dose: 2.8 mg Conference date: March 4, 2026 Presentation time: 11:10–11:40 AM ET +5 more

8 metrics

TONMYA dose 2.8 mg Cyclobenzaprine HCl sublingual tablets strength for fibromyalgia

Conference date March 4, 2026 TD Cowen 46th Annual Healthcare Conference presentation date

Presentation time 11:10–11:40 AM ET Scheduled slot at TD Cowen conference

Barclays meetings window March 10–12 1x1 investor meetings at Barclays Healthcare Conference

Webcast replay period 90 days Length of time conference replay will be accessible

Fibromyalgia treatment gap more than 15 years TONMYA as first new fibromyalgia treatment in this period

Phase 2 trials Phase 2 TONMYA studies in major depressive disorder and acute stress disorder

TNX-2900 stage Phase 2 ready Development stage for Prader-Willi syndrome program

Market Reality Check

Price: $14.29 Vol: Volume 233,534 vs 20-day ...

low vol

$14.29 Last Close

Volume Volume 233,534 vs 20-day average 348,638, indicating relatively subdued trading ahead of the news. low

Technical Shares at $14.29, trading below 200-day MA of $26.56 and 79.58% below the 52-week high.

Peers on Argus

Momentum scanner shows mixed peer action with 1 biotech peer up and 1 down, whil...

1 Up 1 Down

Momentum scanner shows mixed peer action with 1 biotech peer up and 1 down, while TNXP’s own short-term direction was not captured. Sector moves do not appear to explain TNXP’s setup into this conference news.

Historical Context

5 past events · Latest: Jan 30 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 30	Phase 3 data	Positive	-5.4%	Positive Phase 3 RESILIENT fibromyalgia data for TONMYA presented at summit.
Jan 06	Investor conferences	Neutral	+0.9%	January 2026 investor conference presentations and 1x1 meeting availability.
Dec 29	Direct offering	Negative	+0.1%	$20.0M registered direct equity offering to fund commercialization and pipeline.
Dec 29	Program update	Positive	+0.1%	Program updates on TNX-4800 Lyme disease prophylaxis, planning 2026 FDA meeting.
Dec 16	Licensing deal	Positive	-1.4%	Exclusive license of TNX-4900 Sigma-1 antagonist for chronic neuropathic pain.

Pattern Detected

Positive clinical or pipeline news has sometimes coincided with negative or muted price reactions, while financing and conference-related items have not consistently pressured the stock.

Recent Company History

Over the last few months, Tonix reported several milestones, including positive Phase 3 RESILIENT data for TONMYA on Jan 30, 2026 and multiple pipeline updates such as Lyme candidate TNX-4800 and neuropathic pain asset TNX-4900. It also executed a $20.0M registered direct offering on Dec 29, 2025 and expanded ATM capacity via a 424B5 filing. The current March conference participation follows a pattern of ongoing investor outreach alongside clinical and corporate developments.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-09-04

The company has an effective shelf registration on Form S-3/A dated 2025-09-04 with at least one recorded usage via a 424B5 prospectus on 2025-11-21. This provides flexibility to issue additional securities under the program, subject to the terms and effectiveness of the shelf, which is currently noted as not effective in the provided data.

Market Pulse Summary

This announcement highlights Tonix’s ongoing investor engagement through the TD Cowen and Barclays h...

Analysis

This announcement highlights Tonix’s ongoing investor engagement through the TD Cowen and Barclays healthcare conferences, leveraging its commercial CNS platform and recently approved fibromyalgia therapy TONMYA. The company continues to showcase its broader pipeline, including Phase 2-stage and Phase 2-ready programs. Against a backdrop of prior clinical wins, financing activity, and commercial ramp, investors may watch how these conferences shape interest in Tonix’s CNS and immunology portfolio over time.

Key Terms

sublingual, central nervous system, monoclonal antibody, fibromyalgia, +3 more

7 terms

sublingual medical

"TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg)"

Sublingual describes a way to take a drug or supplement by placing it under the tongue so active ingredients are absorbed through the thin tissue there directly into the bloodstream. Like taking a shortcut compared with swallowing a pill, this can produce faster effects, simpler dosing and sometimes more predictable delivery. Investors watch for sublingual formulations because they can affect a product’s market appeal, regulatory pathway, pricing and competitive positioning.

central nervous system medical

"commercial-stage biotechnology company focused on central nervous system (CNS) and immunology"

The central nervous system (CNS) is the body's main control center, made up of the brain and spinal cord, that processes information and directs movement, sensation and basic functions like breathing. For investors, CNS-related products and research matter because they face long development times, strict safety testing and regulatory hurdles; success or failure can dramatically affect a company’s costs, timelines and potential market value.

monoclonal antibody medical

"monoclonal antibody TNX-4800 for Lyme disease prophylaxis"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

fibromyalgia medical

"first new treatment for fibromyalgia in more than 15 years"

Fibromyalgia is a long-term condition that causes widespread body pain, extreme tiredness, and problems with sleep, memory and mood; people often feel unusually sensitive to normal touch or pressure, and symptoms can fluctuate from day to day. It matters to investors because it affects workforce productivity, healthcare spending, and demand for treatments—so advances in diagnostics, drugs, or care delivery can change market size and company prospects, much like a fuel problem that reduces a car’s performance and reliability.

major depressive disorder medical

"evaluate its potential in major depressive disorder and acute stress disorder"

A clinical condition characterized by persistent, severe low mood, loss of interest in daily activities, and reduced ability to function at work or home, lasting weeks or longer. It matters to investors because it drives demand for treatments and mental health services, affects workforce productivity and absenteeism, influences health-care and insurance costs, and shapes risks and opportunities for companies developing drugs, therapies or workplace programs—like a long-lasting storm that lowers economic output.

Prader-Willi syndrome medical

"TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome"

A rare genetic disorder caused by missing or altered instructions on a specific chromosome that leads to constant hunger, low muscle tone, learning challenges, and hormonal problems; think of it as a faulty instruction manual that affects growth, appetite control, and development. Investors care because the condition creates a defined patient population, special regulatory incentives, and long-term medical needs that shape demand for therapies, diagnostics, and care services, influencing market size and risk for drug developers.

webcast technical

"A live webcast of the presentation will be available on the Events page"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

BERKELEY HEIGHTS, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced that the management team will participate in two upcoming investor conferences in March 2026:

TD Cowen 46^th Annual Healthcare Conference
Company Presentation
Presenter: Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals
Date: Wednesday March 4, 2026
Place: Boston Marriott Copley Place
Time: 11:10 AM – 11:40 AM ET
Room: MIT, 3^rd Floor

Barclays 28^th Annual Healthcare Conference
Company Participation
Management will be available for 1x1 meetings, March 10 - 12, at the Loews Miami South Beach Hotel

If you are interested in meeting with Tonix Pharmaceuticals at any of these conferences, please reach out to your respective TD Cowen and Barclays representatives. A live webcast of the presentation will be available on the Events page of the Investors section of the Company’s website at https://ir.tonixpharma.com/news-events. A replay of the webcast will be accessible for 90 days following the event.

Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine products, Zembrace® SymTouch® and Tosymra®. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. In addition, the company’s CNS portfolio includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 including those relating to the completion of the offering, the satisfaction of customary closing conditions, the intended use of proceeds from the offering and other statements that are predictive in nature. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially as a result of a number of factors, including the ability of the Company to satisfy the conditions to the closing of the offering and the timing thereof, as well as those described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 18, 2025, and periodic reports filed with the SEC on or after the date thereof. Tonix does not undertake an obligation to update or revise any forward-looking statement. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contacts
Jessica Morris
Tonix Pharmaceuticals 
investor.relations@tonixpharma.com 
(862) 799-8599 

Brian Korb 
astr partners 
(917) 653-5122 
brian.korb@astrpartners.com 

Media Contacts
Ray Jordan 
Putnam Insights 
ray@putnaminsights.com 

FAQ

When and where will Tonix (TNXP) present at the TD Cowen 46th Annual Healthcare Conference?

Tonix (TNXP) will present at TD Cowen on March 4, 2026, 11:10–11:40 AM ET in Boston. According to the company, Seth Lederman, M.D., CEO, will deliver the presentation and a live webcast will be available on the company's investor events page.

How can investors schedule meetings with Tonix (TNXP) at the Barclays 28th Annual Healthcare Conference on March 10–12, 2026?

Management will be available for 1x1 meetings March 10–12, 2026, at Loews Miami South Beach Hotel. According to the company, interested investors should contact their TD Cowen or Barclays representatives to arrange meetings.

Where will the Tonix (TNXP) March 4, 2026 presentation webcast be hosted and how long is the replay available?

The live webcast will be hosted on the company's Investor Events page and replay will be available for 90 days. According to the company, investors can access the webcast and replay via the Events page on its investor website.

What topics will Tonix (TNXP) management cover during the March 2026 investor presentations?

The presentations will cover commercial progress, the recently approved TONMYA product, and the company's CNS and immunology pipeline. According to the company, management will discuss TONMYA, TNX-2900, TNX-4800, TNX-1500, and related clinical programs.

What is TONMYA and why is it notable for Tonix (TNXP) investors?

TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) is Tonix's recently approved flagship fibromyalgia medicine. According to the company, it is the first new fibromyalgia treatment in more than 15 years and is being evaluated in Phase 2 trials for additional CNS indications.